Sugi Predict

Sugi Predict / Compounds / SCHEMBL5006985

SCHEMBL5006985

SCHEMBL5006985

NC1CC(COCc2ccccc2)C1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.50
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ TAAR1 Q96RJ0 1/20 0.46
▸ NAAA Q02083 1/20 0.44
▸ AGTR2 P50052 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ IDO1 P14902 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ AGXT P21549 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28923696 1.00 TSHR (0.50) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL5006990 1.00 TSHR (0.50) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL3338532 0.91 TSHR (0.52) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL764522 0.91 TSHR (0.52) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL2941662 0.91 TSHR (0.52) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL15642921 0.88 CTSL (0.48) TSHRCTSLCTSBCTSKTAAR1
Hydrochloric Acid SCHEMBL15258725 0.86 CTSL (0.47) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL7280676 0.85 CTSL (0.46) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL23744979 0.84 CTSL (0.50) TSHRCTSLCTSBCTSKTAAR1
SCHEMBL29197662 0.84 CTSL (0.50) TSHRCTSLCTSBCTSKTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 — — US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 — — US disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 — — EP disclosed
CN-116867758-A IRAK degradation agents and uses thereof 凯麦拉医疗公司 2023-10-10 — — CN disclosed
US-20220372016-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-11-24 — — US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
EP-3897631-A1 TARGETED PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2021-10-27 — — EP disclosed
CN-113453679-A Targeted protein degradation C4医药公司 2021-09-28 — — CN disclosed
WO-2020132561-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-06-25 — — WO disclosed
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 — — US disclosed
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 — — US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 — — US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 — — US disclosed
EP-1656379-B1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2007-01-10 — — EP disclosed
CN-1835953-A 4-Cycloalkylaminopyrazolopyrimidine NMDA/NR2B antagonists MERCK & CO INC (US) 2006-09-20 — — CN disclosed
EP-1656379-A1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2006-05-17 — — EP disclosed
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists THOMPSON WAYNE (US) 2005-03-10 — — US disclosed
WO-2005019221-A1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2005-03-03 — — WO disclosed
WO-2005019221-A1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2005-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 TSHR 588/4885CTSL 1833/4885CTSB 1697/4885
US-20220372016-A1 TARGETED PROTEIN DEGRADATION STUB1, MDM2, UBE3A TSHR 2973/4885CTSL 2464/4885CTSB 1126/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A TSHR 2973/4885CTSL 2464/4885CTSB 1126/4885
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A TSHR 2936/4885CTSL 3564/4885CTSB 1645/4885
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists GRIN2B, GRIN1, GRIN2A TSHR 2076/4885CTSL 3982/4885CTSB 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.